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ABSTRACT
Profilin-like protein in Toxoplasma gondii (TgPLP) is a Toll-like receptor (TLR) 
agonist. In this study, we investigated whether TgPLP has an adjuvant effect on 
immune function in autologous whole-tumor-cell vaccine (AWV) treatment. Mice 
vaccinated with AWV together with recombinant TgPLP protein had smaller CT26 
tumors and increased survival. TgPLP treatment strongly increased the production of 
IL-12 through MyD88 signaling and several chemokines, including CCL5, CCL12, and 
XCL1, in bone marrow-derived macrophages (BMMs). In addition, TgPLP increased the 
phagocytosis of tumor cells by BMMs and promoted immune cell mobility on a tumor-
matrigel scaffold. TgPLP triggered immune responses as demonstrated by increased 
expression of antigen presenting cell markers (MHC class I and II, B7.1, and B7.2) 
in BMMs and increased IL-12 and IFN-γ expression in mice. Mice vaccinated with 
AWV and TgPLP had more immune cells (CD4+ and CD8+ T cells, natural killer cells, 
and macrophages) in the spleen and higher total IgG and IgG2a concentrations in 
the blood than mice vaccinated with AWV alone. These findings suggest that TgPLP 
is a TLR-based vaccine adjuvant that enhances antitumor immune responses during 
vaccination with AWV.
INTRODUCTION
Autologous whole-tumor-cell vaccines (AWVs) 
are an established treatment for preventing tumor 
recurrence [1]. Autologous tumor cells are an obvious 
source of tumor-associated antigens (TAAs), but their use 
in cancer vaccination is limited by antigen presentation 
and effector T cell activation [2, 3]. AWVs can be 
produced from surgically resected tumor tissues, but their 
therapeutic effect depends upon the co-administration of 
an immunostimulant [4, 5]. Live cancer cells produce anti-
inflammatory cytokines, such as IL-10 or TGF-β, which 
stimulate immunosuppression by regulatory T cells (Treg) 
known as suppressor T cells [6, 7]. An alternative strategy 
to improving the efficacy of AWV is the stimulation of 
dendritic cells (DCs) or macrophages by TLR signaling, 
which mediates antigen presentation and increases co-
stimulatory surface markers for further T cell function [8].
Toll-like receptors (TLRs) induce IL-12 production 
via MyD88 signaling and improve vaccine efficacy by 
enhancing innate immunity and antigen presentation to 
activate T cells and adaptive immunity [9]. Conserved 
molecular patterns of microbial pathogens [pathogen-
associated molecular patterns (PAMPs)] are TLR ligands 
[10]. For example, lipopolysaccharide (LPS) is recognized 
by TLR4 and flagellin is recognized by TLR5 in bacteria. 
In addition, lipoprotein, lipoteichoic acid, and zymosan are 
recognized by TLR1, TLR2, and TLR6, respectively [10]. 
Recently, profilin-like protein was found in the protozoan 
parasite Toxoplasma gondii (TgPLP) and was recognized 
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by TLR11 in mice and TLR5 in humans [11, 12]. TgPLP 
binds to TLR11 and TLR12 on macrophages and DCs in 
mice [11, 13], and to TLR5 on human peripheral-blood 
mononuclear cells (PBMCs) in humans [12]. Profilin 
contributes to actin polymerization and apicomplexan 
parasites exhibit an actin-dependent gliding mobility 
that is essential for migration across biological barriers 
and invasion of host cells [11]. However, conditional 
disruption of the TgPLP gene in T. gondii prevented 
gliding mobility and TLR 11-dependent IL-12 production 
by host immune cells [11]. This suggested that TgPLP 
is an essential component of gliding mobility as like 
bacterial flagellin and a microbial ligand recognized by 
the host immune system, both of which are important for 
T. gondii infection [11].
Some TLR agonists can be used as vaccine 
adjuvants [14]. TLR3 ligands have been experimentally 
and clinically studied as vaccine adjuvants for HIV, HPV, 
and cancer [15–18]. Agonists that target TLR7, TLR8, and 
TLR9 have also been introduced as therapeutic adjuvants 
for solid tumors and melanomas [19–25]. In particular, 
bacterial flagellin was used as a TLR5 agonist in cancer 
therapy [26, 27]. In this study, we investigated whether 
TgPLP, a TLR11 agonist in mice and a TLR5 agonist in 
humans, represents a vaccine adjuvant for cancer therapy.
T. gondii infection induces cellular immune 
responses, including IL-12 and IFN-γ production [28]. 
We have previously shown that T. gondii infection and the 
administration of T. gondii lysate antigen (TLA) have an 
antitumorigenic effect by increasing IL-12 production and 
decreasing CD31 levels [29]. In addition, euthymic and 
athymic mice produced IL-12 after TLA treatment. The 
enhanced innate immune response may have decreased the 
tumor size by increasing IL-12 production [30]. T. gondii 
infection can also induce tumor immunity, for example, 
by increasing the number of DCs, macrophages, natural 
killer (NK) cells, and CD4+ and CD8+ T cells [31, 32]. T. 
gondii infection decreases tumor growth by Th1 immune 
responses, which activate cytotoxic T cells [33]. B16 
tumor-bearing mice showed decreased tumor growth and 
increased cellular immune responses after treatment with 
excretory and secretory T. gondii antigens [34]. However, 
the molecules in T. gondii that induce antitumorigenic 
effects have not been identified. TgPLP is a potential 
candidate because it is a potent IL-12-inducing protein and 
a TLR agonist, both of which enhance innate immunity 
[35]. To investigate the antitumorigenic effects of TgPLP, 
we produced AWVs from CT26 cancer cells and prepared 
recombinant TgPLP protein. We investigated the TLR-
based antitumorigenic effect of TgPLP in vivo (in BALB/c 
mice) and ex vivo (in BMMs). Our findings suggest that 
TgPLP is a novel cancer-vaccine adjuvant, with general 
applications in the field of tumor vaccination. Our findings 
suggest that TgPLP can be a new potential cancer-vaccine 
adjuvant.
RESULTS
Antitumor activity after vaccination with 
AWV and/or TgPLP in CT26 tumor-bearing 
BALB/c mice
To confirm the antitumorigenic effects of TgPLP 
during vaccination with AWV, BALB/c mice were treated 
with AWV, TgPLP, or AWV+TgPLP. TgPLP protein was 
produced using bacterial expression system, and confirmed 
by Western blot on its purity and specificity (Supplementary 
Figure 1). Mice were vaccinated three times with 1-week 
intervals before CT26 tumor inoculation (Figure 1). Survival 
was then monitored in tumor-induced mice for 90 days 
(Figure 1A). Tumor size was quantified from the 18th day 
after initiation of tumor formation to the 32nd day (Figure 
1B). Tumor mass on the dorsum of mice was significantly 
decreased in the AWV+TgPLP group compared with the 
untreated CT26 tumor group at 20, 22, 28, and 32 days after 
tumor inoculation (p < 0.05, Figure 1B). At this time, tumor 
sizes in other two vaccination group (TgPLP+Tumor and 
AWV+Tumor) were also decreased; however, the difference 
was not statistically significant (Figure 1B).
In addition, survival rates were highest in the 
AWV+TgPLP group with statistical significance (Figure 1A, 
P = 0.0002, log-rank test). CT26-tumor-bearing mice died 
after 40 days, whereas mice in the AWV+TgPLP group died 
after 64 days (Figure 1A). All untreated tumor-bearing mice 
died at day 53, whereas 60% of mice in the AWV+TgPLP 
group survived until the end of the experiment. Tumor 
reduction and survival was highest in the AWV+TgPLP 
group. These findings suggest that TgPLP can be used as a 
vaccine adjuvant to improve the effect of AWV.
Stimulation of MyD88-dependent IL-12 
production by TgPLP in BMMs
BMMs were used to investigate whether TgPLP 
increased IL-12 production through TLR-mediated 
responses ex vivo. TgPLP significantly and continuously 
increased TLR-based IL-12 production by BMMs in culture, 
similar to LPS treatment as a positive control (*p < 0.05, 
Figure 2A). IL-12p35 and IL-12p40 mRNA levels were 
increased more than ten times in BMMs at 12 hours after 
TgPLP treatment (*p < 0.05, Figure 2B). IL-12 production 
was inhibited by treatment with 1 μg MyD88-siRNA (p = 
0.000309, Figure 2C). Western blot analysis showed that 
1 μg MyD88-siRNA abrogated the expression of MyD88 
protein in BMMs (Supplementary Figure 2). These data 
suggest that TgPLP induces IL-12 production in BMMs 
through MyD88 signaling.
Cytokine and chemokine profiles in BMMs after 
TgPLP treatment
To identify the cytokines and chemokines induced 
by TgPLP, we analyzed the culture supernatant of 
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TgPLP-treated BMMs by performing a cytokine protein 
assay using a mouse cytokine array kit. The levels of the 
following cytokines increased by more than two times 
after TgPLP treatment: CCL12 (592.9%), XCL1 (330.9%), 
CCL5 (267.3%), and IL-12p40/p70 (231.8%). In contrast, 
some cytokines were decreased in the BMM supernatant 
after TgPLP treatment, for example, eotaxin (−25.5%), 
VEGF (−29.8%), and CXCL16 (−41.2%) (Figure 3). 
These results show that TgPLP predominantly induces 
the production of cell-attractant chemokines and IL-12 by 
macrophages.
Increased phagocytosis of tumor cells by BMMs 
after TgPLP treatment
The antitumorigenic activity of the TLR agonist 
TgPLP may be increased by macrophage activation, for 
example, during phagocytosis, immune cell infiltration, 
and further cytotoxic T cell activation. To examine 
whether TgPLP increases the phagocytosis of tumor cells 
by BMMs, BMMs were co-cultured with enhanced green 
fluorescent protein (EGFP)-expressing CT26 tumor cells 
to visualize the phagocytosis of tumor cells in the presence 
Figure 1: Tumor reduction in CT26-tumor-bearing BALB/c mice vaccinated with AWV and/or TgPLP. Survival rate (%) 
and changes in tumor size (mm3) in mice vaccinated with AWV and/or TgPLP were investigated and compared with tumor-bearing mice 
without vaccination with AWV and/or TgPLP. A. Survival rates (%) in each experimental group were designated by the ratio compared 
with normal mice (all normal mice survived during the experimental period). B. Tumor size (mm3) in each experimental group between day 
18 and 32 after tumor induction. Tumor sizes in mice vaccinated with TgPLP+AWV were significantly decreased compared with tumor-
bearing mice without vaccination from day 18 when tumor size was monitored. * indicates statistical significance (p < 0.05).
Figure 2: IL-12 production and mRNA expression of the IL-12 subunits (p35 and p40) in BMMs after TgPLP treatment. 
A. IL-12 production was significantly increased by the addition of TgPLP (1 μg/ml) (p < 0.05). B. The induction of IL-12-p35 and -p40 
expression reached peak levels 12 hours after TgPLP treatment as shown by real-time PCR analysis. C. IL-12 production induced by 
TgPLP treatment was dependent upon MyD88 signaling. MyD88 siRNA in BMMs decreased the production of IL-12. * indicates statistical 
significance (p < 0.05).
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of LPS or TgPLP (Figure 4). BMMs were not phagocytic 
in the absence of LPS or TgPLP (Figure 4A, Control). In 
contrast, GFP fluorescence was detected in BMMs treated 
with LPS or TgPLP, indicating the phagocytosis of tumor 
cells (Figure 4A). The increase of GFP fluorescence after 
TgPLP- or LPS treatment compared to untreated control 
was calculated by ImageJ software as a relative indicator 
(%); the result shows that GFP-emitted spots after LPS- 
and TgPLP treatment were increased by 197% and 163%, 
respectively (data not shown).
The increased phagocytic activity of BMMs 
under the treatment of LPS or TgPLP was confirmed by 
FACS analysis using Annexin V- and F4/80-antibodies 
(Figure 4B). The double-positive signals of Annexin V 
(designated for UV-treated apoptotic CT26 cells) and 
F4/80 (designated for BMMs as pan macrophage marker) 
means that CT26 cells are phagocytosed into BMMs. 
The result shows that median fluorescence index (MFI) 
of the double-positive cells with Annexin V and F4/80 
was increased by the treatment of TgPLP as like LPS 
(Figure 4B).
Increased BMM mobility and infiltration in a 
tumor cell-transplanted- and TgPLP-treated 
matrigel scaffold
To examine the effect of TgPLP on immune cell 
activation for antitumorigenesis, we analyzed BMM 
mobility in vitro in a mobility assay (Figure 5A). In 
addition, we measured BMM infiltration in vivo in a 
tumor cell-transplanted matrigel scaffold on the dorsum 
of BALB/c mice (Figure 5B). As revealed by the 
mobility assay, BMM migration was found to be higher 
in TgPLP-treated wells, suggesting an increase in the 
chemotactic movement of TgPLP-treated cells (Figure 
5A). Furthermore, recruited cells around the matrigel 
scaffold on the dorsum of the mice were more abundant in 
AWV+TgPLP-treated mice, as determined by hematoxylin 
and eosin (H&E) and DAPI staining (Figure 5B). The 
abovementioned result was confirmed by the thickness of 
cell layers surrounding the transplanted matrigels, which 
were as follows: untreated (14.5 ± 2.6 μm), AWV-treated 
(16.2 ± 4.1 μm), and AWV+TgPLP-treated matrigels 
Figure 3: Cytokine and chemokine array of BMMs treated with TgPLP. BMMs were incubated with TgPLP (1 μg/ml) for 
24 hours. The concentration of cytokines in the culture supernatant was analyzed using a cytokine array kit. Data represent a relative 
expression rate (%) compared with values in untreated BMMs.
Oncotarget74111www.impactjournals.com/oncotarget
(47.6 ± 8.0 μm) with statistical significance between 
untreated- and AWV+TgPLP-treated matrigels (*p < 0.05, 
Figure 5C).
Increase in antigen presenting cell surface 
markers after TgPLP treatment
MHC antigens and co-stimulation receptors 
are important for the antigen presentation of antigen 
presenting cells (APCs), such as macrophages and DCs. 
MHC molecules (I and II) and B7 molecules [CD80 
(B7.1) and CD86 (B7.2)] bind to TCR and CD28 on T 
cells, respectively. These surface proteins have important 
roles in further adaptive immunity during vaccination with 
AWV. The effect of TgPLP on the expression of antigen 
presenting markers was investigated by FACS analysis and 
shown by the MFI. The expression of MHC molecules (I 
and II) and B7 molecules [CD80 (B7.1) and CD86 (B7.2)] 
Figure 4: Increased phagocytosis in BMMs after TgPLP treatment. A. EGFP+-CT26-cells were exposed by UV for 10 min, and 
then used as target cells. The increase in phagocytic ability of BMMs after TgPLP treatment was observed by fluorescence microscopy. 
Green colored spots represent EGFP+-CT26-cell-engulfed BMMs. The green colored spots increased in LPS- and TgPLP-treated BMMs. 
B. Wild-type CT26 cells were exposed by UV for 10 min, and then used as target cells. The increase in phagocytic ability of BMMs in the 
presence of LPS or TgPLP was observed by FACS analysis. Phycoerythrin (PE)-conjugated antibody against F4/80 and FITC-conjugated 
Annexin V were used for the observation of double positive signals. The data was represented by median fluorescence index (MFI), and 
showed the increase in BMMs that CT26 cells had been phagocytosed.
Figure 5: Increased BMM mobility (in vitro) and cell infiltration into a matrigel TM scaffold (in vivo) after TgPLP 
treatment. A. The mobility assay was performed to investigate the change of chemotactic BMM movement after LPS or TgPLP treatment. 
B. The degree of cell infiltration in mice was investigated using matrigel mixed with AWV and/or TgPLP and visualized by H&E staining 
and DAPI-fluorescence. C. The degree of cell infiltration was measured by the infiltrated cell thickness, which was visualized by H&E 
staining and measured using ImageJ. * indicates statistical significance (p < 0.05).
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was higher in TgPLP-treated BMMs compared with 
LPS-treated BMMs (Figure 6). This suggests that LPS 
as well as TgPLP can activate macrophages for antigen 
presentation.
Cellular and humoral immune characteristics in 
TgPLP-treated mice
To investigate the cellular and humoral immune 
characteristics of mice vaccinated with AWV and/
or TgPLP, mice were subcutaneously injected with 
AWV, TgPLP, or AWV+TgPLP, as described earlier for 
vaccination with AWV (Figure 7). After vaccination, 
mice were sacrificed to examine the immune 
characteristics (cellular and humoral immunity) of the 
blood and cell phenotypes in the spleen (Figures 7 and 
8). Total IL-12 and IFN-γ were significantly increased in 
TgPLP-treated mice regardless of AWV treatment, and 
the increase was greater in AWV+TgPLP-treated mice 
than in TgPLP-treated mice (Figure 7A, 7B). However, 
IgG and IgG2a levels were significantly increased 
in AWV-treated mice but not in TgPLP-treated mice 
(Figure 7C, 7D). This suggests that TgPLP induces 
cytokines such as IL-12 and IFN- γ production in the 
blood, whereas AWV can induce humoral immunity as 
a vaccine effect.
Cell phenotypes in the spleen were examined by 
flow cytometry (Figure 8). Mice treated with TgPLP alone 
did not show changes in cell phenotypes (Figure 8). The 
result was identical to levels in IgG and IgG2a (Figure 7C, 
7D). However, AWV treatment increased significantly the 
number of CD19+ B cells, NK cells (DX5a), macrophages 
(F4/80), CD4+ T cells, and CD8+ T cells, suggesting the 
triggering of an immune response. The number of immune 
cells activated by vaccination with AWV was more 
increased by TgPLP treatment. This strongly suggests 
that vaccination with AWV induces antitumor immunity. 
However, TgPLP is a foreign molecule and cannot induce 
humoral immunity or trigger cellular immunity by itself. 
Instead, it enhances antitumor immunity induced by AWV. 
Taken together, these findings show that TgPLP represents 
a putative vaccine adjuvant.
Figure 6: Increase in antigen presenting cell surface markers after TgPLP treatment. BMMs were cultured with LPS or 
TgPLP and the level of cell surface markers, MHC1, MHC2, CD80 and CD86, were measured by FACS analysis. Data are represented as 
a median fluorescence index (MFI). TgPLP is more effective than LPS at inducing antigen-presentation marker expression.
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DISCUSSION
Immunotherapies for preventing the progression 
and relapse of cancer are being improved, including 
the cancer vaccine, which directly augments anticancer 
immunity. So far, the development of effective cancer 
vaccines has had limited success because of characteristic 
immunosuppression [5]. To develop an effective cancer 
vaccine, the preparation of TAAs and the development 
of vaccine adjuvants are necessary to potentiate the 
immune response [2, 5]. Vaccine adjuvants trigger an 
early innate immune response against TAAs, which is 
essential for promoting further adaptive immunity to 
cancer, such as the activation of cytotoxic CD8+ T cells. 
The TLR response is very important for triggering early 
immune responses because it is recognized by molecular 
pattern and not pathogenic specificity. In addition, it easily 
induces inflammatory cytokines via NF-kb signaling by 
enhancing antigen presentation [36]. PAMPs trigger TLR 
signaling in APCs and have important roles in subsequent 
T cell differentiation and adaptive immunity [37]. For this 
reason, PAMPs have been used as TLR ligands for cancer 
immunotherapy [38]. The present study has identified 
TgPLP derived from T. gondii as a novel cancer-vaccine 
adjuvant.
T. gondii infection increases IL-12 production and 
induces Th1 type host immunity, suggesting the induction 
of cellular immune response [28]. These host immune 
characteristics are similar to anticancer immunity, and 
their antitumorigenic effects have been investigated [29, 
30]. We have previously demonstrated that T. gondii 
infection and treatment with TLA decreases the size of 
S-180 and CT26 tumors in mice [29, 30]. In addition, 
expression of the angiogenesis marker CD31 (PECAM) 
was decreased and IL-12 production was enhanced, 
indicating innate immunity activation [29]. Furthermore, 
the antitumorigenic effect was observed in euthymic and 
athymic nude mice, suggesting that this effect was induced 
by the activation of innate immunity [30, 34]. However, 
the mechanism for the antitumor effect of T. gondii is 
not completely understood. In this study, we investigated 
the ability of T. gondii-derived TgPLP to induce IL-12 
production. TgPLP is a ligand of TLR11 and TLR12 
in mouse and TLR5 in human PBMCs [11–13]. TLR 
Figure 7: Immune characteristics of BALB/c mice vaccinated with AWV and/or TgPLP. After vaccination with AWV 
and/or TgPLP, mouse sera were collected and cytokines (IL-12 and IFN-γ) and immunoglobulins (total IgG and IgG2a) were measured 
using ELISA kit. Data represent mean ± SD (n = 5). * indicates statistical significance (p < 0.05).
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signaling in APCs such as macrophages and DCs induces 
innate and adaptive immune responses, and TLR ligands 
have been investigated as potential vaccine adjuvants 
[38]. To investigate this, we examined whether TgPLP 
treatment increased innate immune responses, including 
macrophage activation, phagocytosis, cell migration, 
and antigen presentation. Our findings demonstrated that 
TgPLP increases IL-12 and IFN-γ production ex vivo and 
in vivo. Furthermore, TgPLP increased BMM mobility 
and immune cell recruitment ex vivo and in vivo. In 
addition, TgPLP increased the production of C/CC motif 
chemokines (CCL12, XCL1, and CCL5), which increase 
the recruitment and mobility of immune cells and are very 
important for antitumorigenesis [38]. XCL1 increases 
chemotactic function and attracts T cells [39]. CCL5 
attracts leukocytes and recruits NK cells in tumor tissues 
[40, 41]. We revealed that the increase in chemokines may 
enhance BMM mobility and infiltration in TgPLP+AWV-
inoculated matrigels. Our results also demonstrated that 
TgPLP increases the expression of antigen presenting 
markers such as MHCs (class I and II) and their co-
stimulatory receptors (CD80 and CD86), which induce 
anticancer immunity and phagocytosis. This means that 
TgPLP-treated cells can induce antigen presentation and 
adaptive T cell immunity [42]. IL-12 is a major cytokine 
responsible for polarizing native T cells to Th1 cells [43]. 
In the present study, we showed that the TLR agonist 
TgPLP acts as an adjuvant during vaccination with AWV 
and does not induce adaptive immune responses by itself. 
Administration of AWV and TgPLP together improved 
vaccine effectiveness, as shown by enhanced survival and 
decreased tumor growth.
Taken together, our results have indicated for the 
first time that TgPLP is a cancer-vaccine adjuvant. TgPLP 
serves as a PAMP to trigger TLR-MyD88 signaling 
and IL-12 production. Specific roles of TgPLP include 
enhancement of cell migration and phagocytosis abilities 
as well as activation of macrophages. TgPLP does not 
induce cellular and humoral immunity by itself but 
augments the effect of AWV when used in combination 
with it. TgPLP promoted the survival of AWV-vaccinated 
mice. This suggests that TgPLP represents a novel 
adjuvant for the treatment of cancer by vaccination with 
AWV.
Figure 8: Spleen cell phenotypes of BALB/c mice vaccinated with AWV and/or TgPLP. After vaccination, spleens were 
harvested and cell populations were examined by FACS analysis. Cell numbers were calculated as the ratio of each cell population (CD19+, 
DX5α+, F4/80+, CD4+ or CD8+) to total splenocyte number. Data present mean ± SD (n = 5). * indicates statistical significance (p < 0.05).
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MATERIALS AND METHODS
Animal ethics
All experiments using BALB/c mice were 
performed in accordance with the ethical standards of 
the IACUC at Seoul National University (SNU-140127-
2-1). 7-week-old female BALB/c mice were purchased 
from Orient Bio (Seongnam, Korea) and housed at room 
temperature with a 12-hour light–dark cycle in SPF 
condition (Seoul National University Hospital Biomedical 
Research Institute, Seoul, Korea).
Preparation of recombinant TgPLP
A 492-bp (165 aa) TgPLP insert was obtained from 
TGME49_293690 (ToxoDB) without single nucleotide 
polymorphisms from T. gondii strains (type 1: GT1, type 
2: ME49, type 3: VEG). The target gene was amplified 
using a pUC57 (Enzynomics, Daejeon, Korea) vector 
with a high copy number, inserted into a pQE80L 
expression vector (N-6-His tagged) (QIAGEN, Hilden, 
Germany) for protein expression, and then transformed 
into E. coli (BL21) (Enzynomics). After selection using 
X-gal (Enzynomics) and ampicillin (50 μg/ml) and IPTG 
induction (0.1 mM), TgPLP recombinant protein was 
extracted with Ni-NTA beads (QIAGEN). TgPLP bound 
with Ni-NTA was washed with washing buffer (50 mM 
NaH2PO4, 200 mM NaCl, 2 mM imidazole adjusted 
to pH 8.0 with NaOH). TgPLP protein was eluted with 
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM 
imidazole, pH 8.0) and desalinated by Amicon Ultra-15 
10K (Milipore, Darmstadt, Germany). Then, endotoxins 
were removed using an endotoxin removal kit (BcMag™, 
SanDiego, CA). After checking for any remaining 
endotoxins with a LAL test kit (ToxinSensor™, GenScript, 
NJ), the final protein solution was aliquoted and stored 
at −80°C until use. The endotoxin level was <0.01 EU/
ml (data not shown). The purity of TgPLP (18 kDa) was 
confirmed by SDS PAGE and Western blot analysis using 
an HRP-conjugated anti-His-antibody (Bethyl, TX). A 
purity of 94% was confirmed using an image analyzer 
software, ImageJ 1.47V (NIH, MD).
EGFP-CT26 tumor cells and wild-type  
CT26 cells
CT26 murine colon carcinoma cells inserted with 
an EGFP plasmid were provided by Dr. Jung Weon Lee at 
the Department of Pharmacy, Seoul National University, 
Seoul, Korea. EGFP-expressing cells were used for in 
vitro phagocytosis assays. Wild-type CT26 cells were 
purchased from the Korean cell line bank (Seoul, Korea). 
Cells were cultured in complete DMEM medium (Gibco-
Life Technologies, Grand Island, NY) containing 10% 
FBS (Invitrogen, Carlsbad, CA) and 1% antibiotics–
antimycotics (Invitrogen); these cells were then sub-
cultured when the cell confluency reached 80% in 100-mm 
culture dish (SPL, Gyeonggi-do, Korea).
Preparation of AWV and the effect of vaccination 
with AWV in BALB/c mice
Tumor formation was induced by injecting 1.0 × 
104 CT26 cells subcutaneously into the dorsum of mice. 
To prepare AWV, 1.0 × 106 CT26 cells were placed in a 
single microcentrifuge tube and attenuated by freezing in 
LN2 and thawing at 37°C; this freeze–thaw process was 
repeated five times. For vaccination experiments, mice 
were divided into five groups (n = 5): normal (untreated), 
positive control (tumor alone), AWV [tumor induction 
after AWV (1 × 106 cells/50 μl) was injected three times 
with a 1-week interval)], TgPLP [tumor induction after 
TgPLP (50 μg/100 μl) was injected three times with a 
1-week interval], and AWV+TgPLP [tumor induction 
after AWV (1 × 106 cells/50 μl) and TgPLP (50 μg/100 
μl) were co-injected three times with a 1-week interval]. 
AWV and/or TgPLP were subcutaneously injected three 
times into the dorsum of mice with a 1-week interval. On 
the following day of the last vaccination, CT26 tumor 
cells were injected, and tumor growth and survival rates 
were observed. Tumor size was measured between day 
18 and day 32 after tumor induction, and calculated using 
the following formula: length × width × height × 0.5. 
Measurements were made using calipers.
BMMs preparation
BMMs were isolated from BALB/c mice (7-week-
old females). Briefly, the bone marrow was isolated by 
flushing with cold complete RPMI medium containing 
10% FBS (Invitrogen) and 1% antibiotics (Invitrogen) 
from the femur and tibia of hind legs. Cells obtained 
from the bone marrow were cultured in 100-mm dishes 
(SPL) in complete RPMI medium containing 30% L929-
conditioned medium (a source of M-CSF). Cells were 
sub-cultured every 3 days. After 2 weeks, the purity was 
measured by FACSCalibur™ (BD bioscience, CA) after 
immunostaining for the macrophage marker F4/80. The 
purity of BMMs exceeded 95% (data not shown).
Gene knockdown using MyD88 siRNA in BMMs
The siRNA Reagent System (Santa Cruz 
Biotechnology, CA) was used for the knockdown of 
MyD88 in BMMs. Transfection was performed according 
to the manufacturer’s instructions. Briefly, BMMs were 
incubated with siRNA transfection medium for 4 hours. 
siRNA and siRNA transfection reagent (both, 1 μg) were 
applied to BMMs and then incubated for 24 hours. The 
transfection efficiency was determined by the transfected 
yield of FITC-conjugated control siRNA and confirmed 
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to be 59.1% (data not shown). In addition, Western blot 
analysis was performed to confirm the knockdown of 
MyD88 protein. MyD88 expression was blocked by 
the treatment with 1 μg siRNA (data not shown). To 
investigate MyD88-dependent IL-12 expression, BMMs 
were cultured with MyD88-siRNA and/or TgPLP (100 ng/
ml) in six-well culture plates. Supernatants were collected 
from cultured BMMs after 24 hours and IL-12 production 
was measured using an ELISA kit (MABTECH, Nacka 
Strand, Sweden).
Quantitation of IL-12 subunits (p35 and p40) 
by real-time PCR
The expression levels of IL-12p35, IL-12p40, 
and β-Actin were measured by TaqMan real-time PCR. 
Primer sequences were as follows: mIL-12p35 forward 
primer: 5′-CCA CCC TTG CCC TCC TAA AC-3′, reverse 
primer: 5′- GTT TTT CTC TGG CCG TCT TCA-3′, 
probe: 5′-FAM- ACC TCA GTT TGG CCA GGG TCA 
TTC CA-TMRA-3′; mIL-12p40 forward primer: 5′-GGA 
AGC ACG GCA GCA GAA TA-3′, reverse primer: 5′- 
AAC TTG AGG GAG AAG TAG GAA TGG-3′, probe: 
5′-FAM-CAT CAT CAA ACC AGA CCC GCC CAA-
TAMRA-3′; β-Actin forward primer: 5′-AGA GGG AAA 
TCG TGC GTG AC-3′, reverse primer: 5′-CAA TAG 
TGA TGA CCT GGC CGT-3′, probe: 5′-FAM-CAC 
TGC CGC ATC CTC TTC CTC CC-TAMRA-3′. For the 
PCR reaction, total RNA was extracted using an RNA 
extraction kit (RNease, QIAGEN), and after checking the 
integrity and purity of total RNA, 200 ng of total RNA 
was reverse transcribed using reverse transcriptase premix 
with oligo d(T)15 primer (EBT-1515, ELPIS biotech, 
Daejeon, Korea). Five microliter of cDNA was used for 
real-time PCR with primers (5 pmol) and probe (500 
pmol). The PCR conditions were as follows: 40 seconds 
at 94°C, 15 seconds at 60°C for annealing, and 60 seconds 
at 72°C for elongation. Amplification was performed 
using the iQ5 real-time detection system (Bio-Rad 
Laboratories, Hercules, CA). To assess the fold change 
of gene expression, Ct values of the housekeeping gene, 
β-actin, were recorded for all cDNA samples. The signals 
for cytokine mRNA were normalized by calculating the 
differences (
Δ
Ct) of Ct
β-actin
 and Ct
cytokine
. Data analysis was 
performed using the 
ΔΔ
Ct calculation.
Cytokine array for BMMs treated with TgPLP
To investigate the cytokine profile in BMMs, they 
were cultured with 1 μg/ml of TgPLP for 24 hours in 
6-well plates until 90% confluency. The supernatant of 
the cultured BMMs was collected and stored at −80°C 
until use. For the cytokine array, samples were analyzed 
using RayBio® Mouse Antibody Array-3 (RayBiotech 
Incorporation, Norcross, GA). The assay was performed 
according to the manufacturer’s instructions. Briefly, 
the array membranes were incubated with blocking 
buffer for 12 hours at room temperature. After washing, 
the membranes were incubated with biotin-conjugated 
antibody for 12 hours at 4°C, and then incubated with 
HRP-conjugated streptavidin for 12 hours. The membranes 
were incubated with detection buffer and exposed by LAS 
1000 System (Fuji, Japan). Finally, the scanned image was 
analyzed by the Multi-Gauge System (Fuji, Japan), and the 
signal intensity was calculated using ImageJ (NIH). After 
the normalization process (comparison between normal 
and positive control), data were represented as the relative 
expression of cytokines and chemokines [30].
Phagocytosis in BMMs treated with TgPLP
To investigate the phagocytic activity of BMMs, 
BMMs were cultured with LPS (50 ng/ml) or TgPLP 
(500 ng/ml) for 24 hours. EGFP-labeled CT26 cells were 
exposed to UV radiation for 10 min to have apoptotic 
characteristics for target cells. After incubation, the 
attached cells were washed with HBSS three times, 
and observed by GFP fluorescence microscope, JuLi™ 
(NanoEnteck, Seoul, Korea). In addition, the phagocytic 
effect of BMMs was also measured by FACS analysis. For 
phagocytosis assay by FACS, the target cells, which are 
the wild type of CT26 cells (Korean cell line back, Seoul, 
Korea), were exposed by UV for 10 min, and then cultured 
with BMMs as an effector cells for 24 hours with LPS (50 
ng/ml) or TgPLP (500 ng/ml). The result was analyzed by 
flow cytometry after double staining with phycoerythrin 
(PE)-conjugated antibody against F4/80 (R&D systems, 
MN, USA) and FITC-conjugated Annexin V (Biolegend). 
MFI was measured using FACS data analyzer, FlowJo 
(Tree Star, OR, USA).
Mobility assay for cell migration
BMMs were cultured in 6-well plates until 90% 
confluency. For the mobility assay, the inner bottom of 
the well was scratched by drawing a line with a white 
tip, and the movement of BMMs into the scratched 
space was observed for 24 hours using a JuLi™ cell 
monitoring system (NanoEnteck, Seoul, Korea) under 
×200 magnification. The experimental conditions were 
as follows: untreated, LPS (50 ng/ml), and TgPLP (500 
ng/ml). Cells that moved into the scratched space were 
represented by a red dot.
Mobility assay of cells infiltrated into an 
AWV+TgPLP-matrigel scaffold
Matrigel (400 μl) (BD Bioscience, Bedford, MA) 
was mixed on ice with 100 μl Hanks’ balanced salt 
solution (Gibco-Life Technologies, Grand Island, NY) 
containing AWV alone or AWV+TgPLP (500 ng/ml). 
Matrigel was subcutaneously injected into the dorsum of 
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BALB/c mice anesthetized by a Zoletil® and Rumpun® 
mixture. After 24 hours, mice were sacrificed and the 
surrounding tissues including the matrigel were harvested 
and fixed with 10% formalin for 24 hours. Then, tissues 
were embedded in paraffin, sliced into 10 μm sections, 
and stained by H&E. H&E staining was observed under a 
microscope. Fluorochrome 4′,6-diamidino-2-pheylindole 
(DAPI) was also observed using a microscope. The 
thickness of infiltrated cell layers around scaffold was 
observed by H&E staining and calculated using ImageJ 
software.
Expression of antigen-presentation surface 
marker in BMMs
Antigen-presentation markers (MHC class I and 
II) and co-stimulation markers (CD80 and CD86) were 
measured in BMMs by flow cytometry after treatment 
with LPS (50 ng/ml) or TgPLP (500 ng/ml) for 24 
hours. Antibodies for immunostaining were as follows: 
APC-conjugated anti-MHC1 (1:100, eBioscience, CA), 
APC-conjugated anti-MHC2 (1:100, eBioscience), 
PE-conjugated anti-CD80 (1:100, eBioscience), FITC-
conjugated anti-CD86 (1:100, eBioscience). For 
immunostaining, BMMs were incubated with each 
antibody for 30 minutes at 4ºC, washed with FACS buffer 
three times, fixed in 4% paraformaldehyde, and analyzed 
by FACSCalibur flow cytometer (BD science). MFI was 
measured by a FlowJo FACS analyzer (Tree Star).
Immune characteristics in the blood and spleen 
of AWV and TgPLP vaccinated mice
BALB/c mice were divided into four groups (n = 
5): control, AWV, TgPLP, or AWV+TgPLP. Mice were 
subcutaneously injected with AWV and/or TgPLP as 
mentioned above. After vaccination, blood was collected 
from the facial vein and IL-12, IFN-γ, total IgG, and 
IgG2a was measured in the sera using sandwich ELISA. 
To examine cell phenotypes in the spleen, splenocytes 
were counted and stained with FACS antibodies, and 
analyzed using FACSCalibur flow cytometer (BD 
science).
ELISA for cellular (IL-12 and IFN-γ) and 
humoral (total IgG and IgG2a) immune 
response factors
Sandwich ELISA of IL-12 (MABTECH, Nacka 
Strand, Sweden) and IFN-γ (BioLegend, CA) was 
performed according to the manufacturer’s instructions. 
Briefly, each capture antibody was coated on a 96 well 
ELISA plate (Corning® Costar®, NY), and nonspecific 
binding was blocked with blocking buffer (0.05% 
Tween-20, 0.1% BSA in PBS). The plate was washed five 
times with PBS containing 0.05% Tween-20 (PBS-T). 
Supernatant (50 μl) of BMMs cultured with TgPLP and/or 
AWV was applied to the plate. After incubation for 2 hours 
and washing with PBS-T, 100 μl of C17.8-biotin (0.5 μg/
ml)-detection antibody was added. After incubation for 1 
hour and washing five times, 100 μl of streptavidin-HRP 
(1:1000) was added. One-hundred microliters of TMB 
(eBioscience) as a substrate of HRP was added to each 
well and the optical density was measured by a micro-
plate reader (US/E-MAX, Molecular Devices, CA). To 
measure IFN-γ expression, 100 μl diluted capture antibody 
was coated to each well. After washing with washing 
buffer (50 mM Tris, 0.14 M NaCl, 0.05% Tween 20, pH 
8.0), the well was blocked with blocking buffer. Each well 
was treated with 50 μl serum for 2 hours. After washing, 
100 μl detection antibody was added and incubated for 1 
hour. Finally, avidin-HRP solution was added, followed 
by treatment with 100 μl TMB. The optical density 
was measured by a plate reader (TECAN, Mӓnnedorf, 
Switzerland). To measure the total IgG and IgG2a in 
TgPLP- or AWV-treated mouse sera, a mouse IgG ELISA 
kit (E90-131, Bethyl) and a mouse IgG2a ELISA kit (E90-
107, Bethyl) were used as described above. The detection 
antibodies were HRP-conjugated and the color reaction 
was performed with TMP solution. The optical density 
was measured at 450 nm.
Phenotypic analysis of splenocytes
Phenotypic changes in splenocytes were analyzed 
using flow cytometry [44]. Spleens were gently crushed 
through a stainless-steel mesh under aseptic conditions 
to remove tissue debris. Spleen erythrocytes were 
destroyed by hypotonic shock using red blood cell lysis 
buffer containing NH4Cl. After washing, splenocytes 
were counted using a Trypan blue exclusion test and 
assigned to FACS staining. Briefly, 100 μl (1 × 106 
cells) of this suspension was stained with rat anti-mouse 
CD16/32 (Fcγ III/II receptor) monoclonal antibodies 
(mAb) (eBioscience). Primary antibodies for the 
phenotype determination of splenocytes were as follows: 
FITC-conjugated anti-mouse mAb against NK cells 
(CD49b, clone DX5, eBioscience), PE-conjugated anti-
mouse mAb against macrophages (F4/80, clone BM8; 
eBioscience), Cy5-conjugated anti-mouse mAb against 
CD8+ T cells (CD8a (LY-2), clone 53-6.7; eBioscience), 
and PE-conjugated anti-mouse mAb against CD4+ T cells 
(CD4 (L3T4), clone GK1.5; eBioscience). Staining was 
performed according to the manufacturer’s protocols. 
Labeled cells were fixed with 4% paraformaldehyde and 
fluorescence was quantified using a BD FACSCalibur 
flow cytometer (BD science). Gates were set to exclude 
nonviable cells and adjusted to detect specifically stained 
cells. Data were originally expressed as percentage of 
splenocytes, and then each cell type was calculated in 
comparison with the total number of spleen cells in each 
mouse.
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Statistical analysis
Survival rates were estimated by the Kaplan–
Meier method and compared between groups with the 
log-rank test using GraphPad Prism 5.0a software. 
Statistical analysis was performed by using 1-way 
analysis of variance (ANOVA) test, and subsequent post 
hoc comparisons were done using GraphPad Prism 5.0a 
software. A p value of < 0.05 was regarded as significant.
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